AI Article Synopsis

  • The controversy over outpatient commitment laws (OCLs) stems from differing cultural values and beliefs related to mental health treatment.
  • In a study of 1,496 Americans, those with hierarchical and communitarian values were generally supportive of OCLs, while egalitarian and individualistic individuals opposed them.
  • The research suggests that cultural values, influenced by emotions, shape perceptions of OCL effectiveness in promoting public health, highlighting the need for informed discussions about these laws.

Article Abstract

What explains controversy over outpatient commitment laws (OCLs), which authorize courts to order persons with mental illness to accept outpatient treatment? We hypothesized that attitudes toward OCLs reflect "cultural cognition" (DiMaggio, P. Annl Rev Sociol 23:263-287, 1997), which motivates individuals to conform their beliefs about policy-relevant facts to their cultural values. In a study involving a diverse sample of Americans (N = 1,496), we found that individuals who are hierarchical and communitarian tend to support OCLs, while those who are egalitarian and individualistic tend to oppose them. These relationships, moreover, fit the cultural cognition hypothesis: that is, rather than directly influencing OCL support, cultural values, mediated by affect, shaped individuals' perceptions of how effectively OCLs promote public health and safety. We discuss the implications for informed public deliberation over OCLs.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10979-008-9174-4DOI Listing

Publication Analysis

Top Keywords

cultural cognition
8
outpatient commitment
8
commitment laws
8
cultural values
8
ocls
5
cultural
4
cognition public
4
public policy
4
policy case
4
case outpatient
4

Similar Publications

Background: Working in inpatient mental health settings is often characterised by highly emotive work and staff shortages. Despite the suggested benefits of reflective practice groups on staff well-being and clinical practice across healthcare settings, to date, there have been limited empirical studies on reflective practice groups in inpatient mental health settings, especially on group engagement and improvement.

Methods: We interviewed fifteen participants, including both facilitators and attendees of reflective practice groups.

View Article and Find Full Text PDF

Exposure to School Racial Segregation and Late-Life Cognitive Outcomes.

JAMA Netw Open

January 2025

Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.

Importance: Disparities in cognition, including dementia occurrence, persist between non-Hispanic Black (hereinafter, Black) and non-Hispanic White (hereinafter, White) older adults, and are possibly influenced by early educational differences stemming from structural racism. However, the association between school racial segregation and later-life cognition remains underexplored.

Objective: To investigate the association between childhood contextual exposure to school racial segregation and cognitive outcomes in later life.

View Article and Find Full Text PDF

To study the neuronal protective effect and its potential mechanism of C16 against gp120-induced cognitive impairment in vitro and in vivo. The NORT method was used to evaluate the short-term memory abilities of rats, the morphological changes in hippocampus were observed by Nissl staining. Cell viability and damage degree were detected by MTT and LDH.

View Article and Find Full Text PDF

Vascular cognitive impairment and dementia (VCID), resulting from chronic cerebral hypoperfusion, represent the second most prevalent form of dementia globally. Aerobic exercise is widely acknowledged as an effective intervention for various cognitive disorders. This study utilized a bilateral common carotid artery stenosis (BCAS) model to investigate whether aerobic exercise promotes cognitive recovery through the Annexin-A1 (ANXA1)/mitogen-activated protein kinase (MAPK) axis in BCAS mice.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is the leading cause of dementia worldwide. The recent announcement that lecanemab, a monoclonal antibody targeting amyloid-b, can slow down cognitive decline in AD is a great step forward in the battle against the disease. However, the modest success achieved in the clinical trial speak to the need for developing additional pharmaceutical approaches to target other key features of AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!